Strategies to Optimize Bone and Cardiovascular Health in BRCA Carriers After Bilateral Salpingo-Oophorectomy

Introduction to BRCA Carriers' Health

• Risk-reducing bilateral salpingo-oophorectomy (RRBSO) reduces ovarian cancer risk by 80-90% and decreases all-cause mortality by 77% in BRCA mutation carriers, according to the National Comprehensive Cancer Network 1

Hormone Replacement Therapy Recommendations

• The American College of Obstetricians and Gynecologists recommends continuing hormone replacement therapy (HRT) until the average age of natural menopause (approximately 50-51 years) for BRCA carriers who have undergone RRBSO, to mitigate bone loss and cardiovascular risks 1
• Short-term HRT after BSO does not appear to decrease the overall benefit of risk reduction for breast cancer in BRCA2 carriers, as suggested by the American Society of Clinical Oncology 2

Monitoring and Surveillance

• The National Comprehensive Cancer Network recommends continuing breast cancer surveillance according to guidelines for BRCA carriers after RRBSO 3, 4